Symbols / ELVN Stock $43.79 -1.46% Enliven Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
ELVN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Stock Fundamentals
Scroll to Statements
Market Cap 2.62B Enterprise Value 2.20B Income -103.69M Sales — Book/sh 7.73 Cash/sh 7.74
Dividend Yield — Payout 0.00% Employees 60 IPO — P/E — Forward P/E -17.24
PEG — P/S — P/B 5.66 P/C — EV/EBITDA -18.39 EV/Sales —
Quick Ratio 27.92 Current Ratio 28.66 Debt/Eq 0.09 LT Debt/Eq — EPS (ttm) -1.83 EPS next Y -2.54
EPS Growth — Revenue Growth — Earnings 2026-05-13 ROA -18.65% ROE -26.95% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 59.80M Shs Float 34.14M Short Float 14.36%
Short Ratio 3.94 Short Interest — 52W High 48.53 52W Low 14.79 Beta 0.49 Avg Volume 1.15M
Volume 312.67K Target Price $51.29 Recom Strong_buy Prev Close $44.44 Price $43.79 Change -1.46%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$51.29
Mean price target
2. Current target
$43.79
Latest analyst target
3. DCF / Fair value
$-14.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$43.79
Low
$41.00
High
$60.00
Mean
$51.29

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main HC Wainwright & Co. Buy → Buy $56
2026-03-25 main Mizuho Outperform → Outperform $45
2025-07-02 main HC Wainwright & Co. Buy → Buy $48
2025-06-16 init Goldman Sachs — → Buy $37
2025-06-16 main Baird Outperform → Outperform $52
2025-05-16 main Jones Trading Buy → Buy $27
2025-05-15 main HC Wainwright & Co. Buy → Buy $40
2025-03-21 main HC Wainwright & Co. Buy → Buy $39
2024-12-13 init BTIG — → Buy $42
2024-11-15 main Baird Outperform → Outperform $40
2024-10-31 init Jones Trading — → Buy $36
2024-10-01 reit HC Wainwright & Co. Buy → Buy $37
2024-09-09 init HC Wainwright & Co. — → Buy $37
2024-06-11 init Baird — → Outperform $32
2024-04-09 init Mizuho — → Buy $34
2023-03-29 init Jefferies — → Buy $27
2023-03-03 init TD Cowen — → Outperform —
News
RSS: Latest ELVN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-17 COLLINS HELEN LOUISE Officer — 5,000 $45.81 $238,352
2026-04-17 COLLINS HELEN LOUISE Officer — 5,000 $2.48 $12,400
2026-03-25 COLLINS HELEN LOUISE Officer — 40,000 $35.10 $1,404,024
2026-03-25 COLLINS HELEN LOUISE Officer — 40,000 $2.48 $99,200
2026-03-17 COLLINS HELEN LOUISE Officer — 5,000 $27.76 $138,800
2026-03-17 COLLINS HELEN LOUISE Officer — 5,000 $2.48 $12,400
2026-03-10 COLLINS HELEN LOUISE Officer — 40,000 $30.02 $1,202,638
2026-03-10 COLLINS HELEN LOUISE Officer — 40,000 $2.48 $99,200
2026-03-06 HOHL BENJAMIN Chief Financial Officer — 10,000 $29.58 $295,839
2026-02-17 HEYMAN RICHARD A Director — 1,230 $26.18 $32,196
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
119.66
+14.45%
104.55
+25.17%
83.53
+115.33%
38.79
Research And Development
85.86
+6.29%
80.78
+25.09%
64.57
+108.16%
31.02
Selling General And Administration
33.80
+42.17%
23.78
+25.43%
18.95
+143.98%
7.77
General And Administrative Expense
33.80
+42.17%
23.78
+25.43%
18.95
+143.98%
7.77
Other Gand A
33.80
+42.17%
23.78
+25.43%
18.95
+143.98%
7.77
Total Expenses
119.66
+14.45%
104.55
+25.17%
83.53
+115.33%
38.79
Operating Income
-119.66
-14.45%
-104.55
-25.17%
-83.53
-115.33%
-38.79
Total Operating Income As Reported
-119.66
-14.45%
-104.55
-25.17%
-83.53
-115.33%
-38.79
EBITDA
-119.39
-14.54%
-104.24
-25.24%
-83.23
-115.76%
-38.58
Normalized EBITDA
-119.39
-13.59%
-105.11
-26.29%
-83.23
-115.76%
-38.58
Reconciled Depreciation
0.26
-17.03%
0.32
+6.73%
0.30
+38.14%
0.21
EBIT
-119.66
-14.45%
-104.55
-25.17%
-83.53
-115.33%
-38.79
Total Unusual Items
0.00
-100.00%
0.87
0.00
—
Total Unusual Items Excluding Goodwill
0.00
-100.00%
0.87
0.00
—
Special Income Charges
0.00
-100.00%
0.87
0.00
—
Restructuring And Mergern Acquisition
0.00
+100.00%
-0.87
0.00
—
Net Income
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Pretax Income
-103.69
-16.78%
-88.79
-24.04%
-71.58
-90.07%
-37.66
Net Non Operating Interest Income Expense
16.01
+7.53%
14.89
+24.43%
11.97
+959.96%
1.13
Net Interest Income
16.01
+7.53%
14.89
+24.43%
11.97
+959.96%
1.13
Interest Income Non Operating
16.01
+7.53%
14.89
+24.43%
11.97
+959.96%
1.13
Interest Income
16.01
+7.53%
14.89
+24.43%
11.97
+959.96%
1.13
Other Income Expense
-0.05
-105.63%
0.87
+4059.09%
-0.02
—
Other Non Operating Income Expenses
-0.05
-2350.00%
-0.00
+90.91%
-0.02
—
Tax Provision
0.00
-100.00%
0.23
0.00
—
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.18
0.00
0.00
Net Income Including Noncontrolling Interests
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Net Income From Continuing Operation Net Minority Interest
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Net Income From Continuing And Discontinued Operation
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Net Income Continuous Operations
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Normalized Income
-103.69
-15.58%
-89.71
-25.33%
-71.58
-90.07%
-37.66
Net Income Common Stockholders
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Diluted EPS
—
-1.89
+5.97%
-2.01
-119.35%
-0.92
Basic EPS
—
-1.89
+5.97%
-2.01
-119.35%
-0.92
Basic Average Shares
—
47.07
+32.43%
35.55
-13.51%
41.10
Diluted Average Shares
—
47.07
+32.43%
35.55
-13.51%
41.10
Diluted NI Availto Com Stockholders
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
476.17
+46.17%
325.76
+19.82%
271.87
+226.38%
83.30
Current Assets
474.88
+49.27%
318.13
+19.53%
266.15
+242.30%
77.75
Cash Cash Equivalents And Short Term Investments
462.62
+47.59%
313.44
+23.82%
253.15
+235.14%
75.54
Cash And Cash Equivalents
98.90
-20.32%
124.12
+23.94%
100.14
+32.57%
75.54
Other Short Term Investments
363.73
+92.12%
189.32
+23.73%
153.01
0.00
Restricted Cash
0.00
-100.00%
0.05
+0.00%
0.05
0.00
Other Current Assets
12.26
+164.56%
4.63
-64.22%
12.95
+484.08%
2.22
Total Non Current Assets
1.29
-83.10%
7.63
+33.54%
5.72
+3.08%
5.54
Net PPE
0.42
-8.95%
0.46
-56.87%
1.06
-29.95%
1.52
Gross PPE
0.65
-53.09%
1.38
-20.54%
1.73
-8.31%
1.89
Accumulated Depreciation
-0.23
+75.08%
-0.92
-36.96%
-0.67
-79.41%
-0.37
Machinery Furniture Equipment
0.26
-0.38%
0.26
+18.92%
0.22
+204.11%
0.07
Other Properties
0.38
-65.59%
1.11
-26.34%
1.51
-16.84%
1.82
Non Current Deferred Assets
0.22
0.00
-100.00%
0.56
-85.84%
3.98
Other Non Current Assets
0.66
-90.86%
7.17
+75.38%
4.09
+7475.93%
0.05
Total Liabilities Net Minority Interest
16.57
+4.10%
15.91
-38.70%
25.96
-83.79%
160.12
Current Liabilities
16.57
+4.10%
15.91
-38.54%
25.89
+166.54%
9.71
Payables And Accrued Expenses
11.52
+3.79%
11.10
-6.45%
11.87
+74.13%
6.82
Payables
2.16
+60.88%
1.34
+152.26%
0.53
-84.53%
3.44
Accounts Payable
2.16
+60.88%
1.34
+152.26%
0.53
-84.53%
3.44
Current Accrued Expenses
9.36
-4.06%
9.76
-13.90%
11.34
+235.65%
3.38
Pensionand Other Post Retirement Benefit Plans Current
4.29
-6.81%
4.61
+38.49%
3.33
+56.24%
2.13
Current Debt And Capital Lease Obligation
0.40
—
0.34
+3.72%
0.32
Current Capital Lease Obligation
0.40
0.00
-100.00%
0.34
+3.72%
0.32
Other Current Liabilities
0.35
+72.06%
0.20
-98.03%
10.36
+2218.57%
0.45
Total Non Current Liabilities Net Minority Interest
0.00
0.00
-100.00%
0.07
-99.96%
150.41
Other Non Current Liabilities
—
—
0.07
-89.83%
0.66
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
149.75
Stockholders Equity
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Common Stock Equity
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Capital Stock
0.06
+20.41%
0.05
+19.51%
0.04
+4000.00%
0.00
Common Stock
0.06
+20.41%
0.05
+19.51%
0.04
+4000.00%
0.00
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
59.44
+21.46%
48.94
+18.51%
41.29
+0.47%
41.10
Ordinary Shares Number
59.44
+21.46%
48.94
+18.51%
41.29
+0.47%
41.10
Additional Paid In Capital
806.37
+45.76%
553.21
+38.24%
400.17
+6527.56%
6.04
Retained Earnings
-347.17
-42.59%
-243.47
-57.64%
-154.45
-86.39%
-82.86
Gains Losses Not Affecting Retained Earnings
0.33
+507.27%
0.06
-60.99%
0.14
0.00
Other Equity Adjustments
0.33
+507.27%
0.06
-60.99%
0.14
—
Total Equity Gross Minority Interest
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Total Capitalization
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Working Capital
458.31
+51.65%
302.21
+25.79%
240.26
+253.12%
68.04
Invested Capital
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Total Debt
0.40
0.00
-100.00%
0.34
+3.72%
0.32
Capital Lease Obligations
0.40
0.00
-100.00%
0.34
+3.72%
0.32
Net Tangible Assets
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Tangible Book Value
459.60
+48.33%
309.85
+26.00%
245.91
+420.09%
-76.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-70.30
+3.95%
-73.19
-19.46%
-61.27
-91.01%
-32.08
Cash Flow From Continuing Operating Activities
-70.30
+3.95%
-73.19
-19.46%
-61.27
-91.01%
-32.08
Net Income From Continuing Operations
-103.69
-16.48%
-89.02
-24.36%
-71.58
-90.07%
-37.66
Depreciation Amortization Depletion
0.26
-17.03%
0.32
+6.73%
0.30
+38.14%
0.21
Depreciation
0.26
-17.03%
0.32
+6.73%
0.30
+38.14%
0.21
Depreciation And Amortization
0.26
-17.03%
0.32
+6.73%
0.30
+38.14%
0.21
Other Non Cash Items
0.35
+163.83%
-0.55
-280.72%
0.31
—
Stock Based Compensation
34.02
+68.63%
20.17
+56.22%
12.91
+304.70%
3.19
Asset Impairment Charge
—
—
0.00
-100.00%
1.74
Operating Gains Losses
0.11
+863.64%
0.01
—
—
Gain Loss On Sale Of PPE
0.11
+863.64%
0.01
0.00
—
Change In Working Capital
-1.12
+75.31%
-4.54
-424.13%
1.40
+219.86%
0.44
Change In Prepaid Assets
-1.10
+76.82%
-4.77
-28.76%
-3.70
-132.89%
-1.59
Change In Payables And Accrued Expense
0.32
-42.88%
0.56
-89.62%
5.41
+167.49%
2.02
Change In Accrued Expense
-0.50
-100.00%
-0.25
-103.24%
7.66
+375.14%
1.61
Change In Payable
0.82
+0.86%
0.81
+136.00%
-2.25
-647.45%
0.41
Change In Account Payable
0.82
+0.86%
0.81
+136.00%
-2.25
-647.45%
0.41
Change In Other Current Assets
—
—
—
—
Change In Other Current Liabilities
-0.34
-0.60%
-0.34
-8.06%
-0.31
-7850.00%
0.00
Investing Cash Flow
-173.84
-382.93%
-36.00
+75.75%
-148.41
-24150.33%
-0.61
Cash Flow From Continuing Investing Activities
-173.84
-382.93%
-36.00
+75.75%
-148.41
-24150.33%
-0.61
Net PPE Purchase And Sale
0.06
+225.00%
-0.04
+70.47%
-0.15
+75.65%
-0.61
Purchase Of PPE
-0.16
-259.09%
-0.04
+70.47%
-0.15
+75.65%
-0.61
Sale Of PPE
0.21
0.00
—
—
Capital Expenditure
-0.16
-259.09%
-0.04
+70.47%
-0.15
+75.65%
-0.61
Net Investment Purchase And Sale
-173.90
-372.21%
-36.83
+75.16%
-148.26
0.00
Purchase Of Investment
-446.79
-27.39%
-350.74
-30.74%
-268.26
0.00
Sale Of Investment
272.90
-13.07%
313.91
+161.60%
120.00
0.00
Net Other Investing Changes
—
0.87
—
—
Financing Cash Flow
218.87
+64.36%
133.16
-43.16%
234.29
+13123.12%
-1.80
Cash Flow From Continuing Financing Activities
218.87
+64.36%
133.16
-43.16%
234.29
+13123.12%
-1.80
Net Common Stock Issuance
216.17
+67.72%
128.88
0.00
—
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
2.92
-31.92%
4.28
+973.18%
0.40
-32.49%
0.59
Net Other Financing Charges
-0.22
—
233.89
+9886.07%
-2.39
Changes In Cash
-25.27
-205.42%
23.98
-2.56%
24.61
+171.34%
-34.49
Beginning Cash Position
124.17
+23.93%
100.19
+32.55%
75.59
-31.33%
110.08
End Cash Position
98.90
-20.35%
124.17
+23.93%
100.19
+32.55%
75.59
Free Cash Flow
-70.46
+3.79%
-73.24
-19.24%
-61.42
-87.89%
-32.69
Income Tax Paid Supplemental Data
0.00
-100.00%
0.23
0.00
—
Amortization Of Securities
-0.23
-153.54%
0.42
+109.21%
-4.60
0.00
Common Stock Issuance
216.17
+67.72%
128.88
0.00
—
Issuance Of Capital Stock
216.17
+67.72%
128.88
0.00
—
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Payments
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category